Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
Werewolf Therapeutics (Nasdaq: HOWL) has announced the appointment of Anil Singhal, Ph.D., President and CEO of Trishula Therapeutics, to its board of directors. Dr. Singhal brings over 30 years of oncology research and development leadership experience to HOWL's board. He previously served as President and CEO of Adicet Bio, where he led the company to its first oncology IND submission and merger with resTOR bio.
The appointment coincides with the planned resignation of Derek DiRocco from the board, effective at the company's 2025 annual meeting of stockholders. DiRocco has served on the board since joining during the Series B funding round led by RA Capital in 2020.
Werewolf Therapeutics focuses on developing conditionally activated therapeutics using its PREDATOR protein engineering platform to stimulate the immune system for treating cancer and immunological diseases.
Werewolf Therapeutics (Nasdaq: HOWL) ha annunciato la nomina di Anil Singhal, Ph.D., Presidente e CEO di Trishula Therapeutics, nel suo consiglio di amministrazione. Il Dr. Singhal porta oltre 30 anni di esperienza nella ricerca e nello sviluppo in oncologia al consiglio di HOWL. In precedenza, ha ricoperto il ruolo di Presidente e CEO di Adicet Bio, dove ha guidato l'azienda verso la sua prima presentazione di IND in oncologia e la fusione con resTOR bio.
La nomina coincide con la prevista dimissione di Derek DiRocco dal consiglio, che sarà efficace durante l'assemblea annuale degli azionisti del 2025. DiRocco è stato membro del consiglio da quando si è unito durante il round di finanziamento di Serie B guidato da RA Capital nel 2020.
Werewolf Therapeutics si concentra sullo sviluppo di terapie attivate condizionatamente utilizzando la sua piattaforma di ingegneria proteica PREDATOR per stimolare il sistema immunitario nel trattamento del cancro e delle malattie immunologiche.
Werewolf Therapeutics (Nasdaq: HOWL) ha anunciado el nombramiento de Anil Singhal, Ph.D., Presidente y CEO de Trishula Therapeutics, en su junta directiva. El Dr. Singhal aporta más de 30 años de experiencia en liderazgo en investigación y desarrollo oncológico a la junta de HOWL. Anteriormente, se desempeñó como Presidente y CEO de Adicet Bio, donde llevó a la empresa a su primera presentación de IND oncológica y a la fusión con resTOR bio.
El nombramiento coincide con la renuncia planeada de Derek DiRocco de la junta, que será efectiva en la reunión anual de accionistas de la compañía en 2025. DiRocco ha sido miembro de la junta desde que se unió durante la ronda de financiamiento de Serie B liderada por RA Capital en 2020.
Werewolf Therapeutics se centra en desarrollar terapias activadas condicionalmente utilizando su plataforma de ingeniería de proteínas PREDATOR para estimular el sistema inmunológico en el tratamiento del cáncer y enfermedades inmunológicas.
Werewolf Therapeutics (Nasdaq: HOWL)는 Anil Singhal, Ph.D., Trishula Therapeutics의 회장 겸 CEO를 이사회의 새로운 멤버로 임명했다고 발표했습니다. Singhal 박사는 HOWL 이사회에 30년 이상의 종양학 연구 및 개발 리더십 경험을 제공합니다. 그는 이전에 Adicet Bio의 회장 겸 CEO로 재직하며 회사의 첫 종양학 IND 제출 및 resTOR bio와의 합병을 이끌었습니다.
이번 임명은 Derek DiRocco가 2025년 주주 연례 회의에서 이사회에서 사임할 예정인 것과 동시에 이루어졌습니다. DiRocco는 2020년 RA Capital이 주도한 시리즈 B 자금 조달 라운드에 참여하면서 이사회에 합류했습니다.
Werewolf Therapeutics는 PREDATOR 단백질 공학 플랫폼을 사용하여 면역 체계를 자극하여 암 및 면역 질환을 치료하는 조건부 활성화 치료제를 개발하는 데 주력하고 있습니다.
Werewolf Therapeutics (Nasdaq: HOWL) a annoncé la nomination de Anil Singhal, Ph.D., Président et CEO de Trishula Therapeutics, au sein de son conseil d'administration. Le Dr Singhal apporte plus de 30 ans d'expérience en recherche et développement en oncologie au conseil de HOWL. Auparavant, il a été Président et CEO d'Adicet Bio, où il a conduit l'entreprise à sa première soumission d'IND en oncologie et à sa fusion avec resTOR bio.
Cette nomination coïncide avec la démission prévue de Derek DiRocco du conseil, effective lors de l'assemblée annuelle des actionnaires de l'entreprise en 2025. DiRocco siège au conseil depuis son adhésion lors du tour de financement de Série B dirigé par RA Capital en 2020.
Werewolf Therapeutics se concentre sur le développement de thérapies activées de manière conditionnelle en utilisant sa plateforme d'ingénierie protéique PREDATOR pour stimuler le système immunitaire dans le traitement du cancer et des maladies immunologiques.
Werewolf Therapeutics (Nasdaq: HOWL) hat die Ernennung von Anil Singhal, Ph.D., Präsident und CEO von Trishula Therapeutics, in seinen Vorstand bekannt gegeben. Dr. Singhal bringt über 30 Jahre Erfahrung in der Leitung von Forschung und Entwicklung im Bereich Onkologie in den Vorstand von HOWL ein. Zuvor war er Präsident und CEO von Adicet Bio, wo er das Unternehmen zu seiner ersten IND-Einreichung im Bereich Onkologie und zur Fusion mit resTOR bio führte.
Die Ernennung fällt mit dem geplanten Rücktritt von Derek DiRocco aus dem Vorstand zusammen, der bei der Hauptversammlung der Aktionäre des Unternehmens im Jahr 2025 wirksam wird. DiRocco ist seit seinem Eintritt während der Finanzierungsrunde der Serie B, die 2020 von RA Capital geleitet wurde, im Vorstand tätig.
Werewolf Therapeutics konzentriert sich auf die Entwicklung von bedingt aktivierten Therapeutika, die ihre PREDATOR-Protein-Engineering-Plattform nutzen, um das Immunsystem zur Behandlung von Krebs und immunologischen Erkrankungen zu stimulieren.
- Addition of experienced executive with 30+ years of oncology R&D leadership
- Strengthening of board expertise in biopharmaceutical development and clinical trials
- Maintained continuity in board transition with planned resignation announcement
- None.
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors.
“I am thrilled to join Werewolf’s board of directors as the company advances its novel INDUKINE molecules through clinical development,” said Dr. Singhal. “Werewolf is demonstrating the power of the PREDATORTM protein engineering platform and its potential to provide safer and more efficacious treatments for cancer and immunological diseases.”
“I am pleased to welcome Dr. Singhal to our board of directors at this exciting time for our company,” added Luke Evnin, Ph.D., Chairman of the Board of Directors and co-founder of Werewolf Therapeutics. “With over 30 years of oncology research and development leadership and execution, Dr. Singhal’s proven experience represents a critical addition to our board’s skill set.”
Dr. Singhal joins the board of Werewolf Therapeutics with over three decades of research and development experience in the biopharmaceutical industry. Dr. Singhal is the President and Chief Executive Officer of Trishula Therapeutics, Inc., a private biotechnology company. Prior to that, Dr. Singhal served as the President and Chief Executive Officer and a member of the board of directors of Adicet Bio, Inc., where he led the then-private biotechnology company to its first oncology investigational new drug application submission and its merger with resTOR bio, Inc. Dr. Singhal is a member of the American Association of Cancer Research and a member of the American Society of Clinical Oncology. Dr. Singhal received his B.Sc Honours degree in Biochemistry from Panjab University in India, his MBA in Business Administration from the University of Washington and his Ph.D. in Biochemistry from Rutgers University.
Concurrent with the appointment of Dr. Singhal, Werewolf announced that Derek DiRocco plans to resign as a director of the Company, effective as of the Company’s 2025 annual meeting of stockholders. Dr. DiRocco has been a very valuable member of the Werewolf board since joining at the Series B raise led by RA Capital in 2020, and the Company appreciates his years of representation and support.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
FAQ
Who is the new board member appointed to Werewolf Therapeutics (HOWL)?
What experience does Dr. Singhal bring to HOWL's board?
Who is leaving Werewolf Therapeutics' board in 2025?
What is Werewolf Therapeutics' (HOWL) main technology platform?
